Entera Bio Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Cytokinetics’ Omecamtiv For Heart Failure Cytokinetics, Inc. is expected to release top-line data from the Phase III METEORIC-HF study of omecamtiv mecarbil, a selective cardiac myosin activator, by

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Newly Public Millendo Advanc

Biopharmaceutical companies that launched initial public offerings in the US during the first half of 2018 posted an average return of 20.9% as of July 3, stabilizing after the valuation rollercoaster